The global retinoic acid receptor beta market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by the increasing prevalence of metabolic disorders and oncology in developing countries such as India and China. The increasing number of patients with metabolic disorders and oncology in these countries has led to an increase in demand for retinoic acid receptor beta drugs, which are used for treatment purposes.
Alitretinoin is expected to be the fastest-growing type segment during the forecast period, owing to its efficacy against various types of cancer such as leukemia, lymphoma, breast cancer, lung cancer, prostate cancer and skin cancers. Alitretinoin also has a lower risk of side effects than other types of retinoids due to its low toxicity levels. SB073 is expected to be the second-fastest growing type segment due to its high efficacy against various types of cancers such as leukemia and lymphoma; it also has a lower risk profile than other types because it does not cause any adverse effects on reproductive organs or bone marrow cells like tamibarotene or tazarotene do.
- The Retinoic Acid Receptor Beta market is expected to grow at a CAGR of XX% during the forecast period.
- Increasing prevalence of skin diseases such as acne and psoriasis is driving the growth of the Retinoic Acid Receptor Beta market.
- Increasing awareness about skin care products among consumers is also driving the growth of the Retinoic Acid Receptor Beta market.
- The increasing number of cosmetic surgeries and treatments for skin disorders are also driving the growth of this market segment in recent years, which has led to an increase in demand for retinoids, which are used as a treatment for these conditions, thereby fueling its growth over time 5) Increasing research and development activities by pharmaceutical companies on new retinoid formulations are expected to fuel its growth over time.
Industry Growth Insights published a new data on “Retinoic Acid Receptor Beta Market”. The research report is titled “Retinoic Acid Receptor Beta Market research by Types (Alitretinoin, SBD-073, Tamibarotene, Tazarotene, Others), By Applications (Metabolic Disorders, Hemotological Disorders, Oncology, Others), By Players/Companies 3SBio Inc, Lee's Pharmaceutical Holdings Ltd, Phosphagenics Ltd, Promius Pharma LLC, Sol-Gel Technologies Ltd, Valeant Pharmaceuticals International Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Retinoic Acid Receptor Beta Market Research Report
By Type
Alitretinoin, SBD-073, Tamibarotene, Tazarotene, Others
By Application
Metabolic Disorders, Hemotological Disorders, Oncology, Others
By Companies
3SBio Inc, Lee's Pharmaceutical Holdings Ltd, Phosphagenics Ltd, Promius Pharma LLC, Sol-Gel Technologies Ltd, Valeant Pharmaceuticals International Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Retinoic Acid Receptor Beta Market Report Segments:
The global Retinoic Acid Receptor Beta market is segmented on the basis of:
Types
Alitretinoin, SBD-073, Tamibarotene, Tazarotene, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Metabolic Disorders, Hemotological Disorders, Oncology, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- 3SBio Inc
- Lee's Pharmaceutical Holdings Ltd
- Phosphagenics Ltd
- Promius Pharma LLC
- Sol-Gel Technologies Ltd
- Valeant Pharmaceuticals International Inc
Highlights of The Retinoic Acid Receptor Beta Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alitretinoin
- SBD-073
- Tamibarotene
- Tazarotene
- Others
- By Application:
- Metabolic Disorders
- Hemotological Disorders
- Oncology
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Retinoic Acid Receptor Beta Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Retinoic acid receptor beta (RARB) is a protein that binds retinoids, including retinol and its derivatives. Retinoic acid receptors are found in the skin, hair follicles, and other tissues. They play an important role in the development of the skin and hair.
Some of the major players in the retinoic acid receptor beta market are 3SBio Inc, Lee's Pharmaceutical Holdings Ltd, Phosphagenics Ltd, Promius Pharma LLC, Sol-Gel Technologies Ltd, Valeant Pharmaceuticals International Inc.
The retinoic acid receptor beta market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Retinoic Acid Receptor Beta Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Retinoic Acid Receptor Beta Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Retinoic Acid Receptor Beta Market - Supply Chain
4.5. Global Retinoic Acid Receptor Beta Market Forecast
4.5.1. Retinoic Acid Receptor Beta Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Retinoic Acid Receptor Beta Market Size (000 Units) and Y-o-Y Growth
4.5.3. Retinoic Acid Receptor Beta Market Absolute $ Opportunity
5. Global Retinoic Acid Receptor Beta Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Retinoic Acid Receptor Beta Market Size and Volume Forecast by Type
5.3.1. Alitretinoin
5.3.2. SBD-073
5.3.3. Tamibarotene
5.3.4. Tazarotene
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Retinoic Acid Receptor Beta Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Retinoic Acid Receptor Beta Market Size and Volume Forecast by Application
6.3.1. Metabolic Disorders
6.3.2. Hemotological Disorders
6.3.3. Oncology
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Retinoic Acid Receptor Beta Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Retinoic Acid Receptor Beta Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Retinoic Acid Receptor Beta Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Retinoic Acid Receptor Beta Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Retinoic Acid Receptor Beta Demand Share Forecast, 2019-2026
9. North America Retinoic Acid Receptor Beta Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Retinoic Acid Receptor Beta Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Retinoic Acid Receptor Beta Market Size and Volume Forecast by Application
9.4.1. Metabolic Disorders
9.4.2. Hemotological Disorders
9.4.3. Oncology
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Retinoic Acid Receptor Beta Market Size and Volume Forecast by Type
9.7.1. Alitretinoin
9.7.2. SBD-073
9.7.3. Tamibarotene
9.7.4. Tazarotene
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Retinoic Acid Receptor Beta Demand Share Forecast, 2019-2026
10. Latin America Retinoic Acid Receptor Beta Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Retinoic Acid Receptor Beta Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Retinoic Acid Receptor Beta Market Size and Volume Forecast by Application
10.4.1. Metabolic Disorders
10.4.2. Hemotological Disorders
10.4.3. Oncology
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Retinoic Acid Receptor Beta Market Size and Volume Forecast by Type
10.7.1. Alitretinoin
10.7.2. SBD-073
10.7.3. Tamibarotene
10.7.4. Tazarotene
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Retinoic Acid Receptor Beta Demand Share Forecast, 2019-2026
11. Europe Retinoic Acid Receptor Beta Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Retinoic Acid Receptor Beta Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Retinoic Acid Receptor Beta Market Size and Volume Forecast by Application
11.4.1. Metabolic Disorders
11.4.2. Hemotological Disorders
11.4.3. Oncology
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Retinoic Acid Receptor Beta Market Size and Volume Forecast by Type
11.7.1. Alitretinoin
11.7.2. SBD-073
11.7.3. Tamibarotene
11.7.4. Tazarotene
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Retinoic Acid Receptor Beta Demand Share, 2019-2026
12. Asia Pacific Retinoic Acid Receptor Beta Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Retinoic Acid Receptor Beta Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Retinoic Acid Receptor Beta Market Size and Volume Forecast by Application
12.4.1. Metabolic Disorders
12.4.2. Hemotological Disorders
12.4.3. Oncology
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Retinoic Acid Receptor Beta Market Size and Volume Forecast by Type
12.7.1. Alitretinoin
12.7.2. SBD-073
12.7.3. Tamibarotene
12.7.4. Tazarotene
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Retinoic Acid Receptor Beta Demand Share, 2019-2026
13. Middle East & Africa Retinoic Acid Receptor Beta Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Retinoic Acid Receptor Beta Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Retinoic Acid Receptor Beta Market Size and Volume Forecast by Application
13.4.1. Metabolic Disorders
13.4.2. Hemotological Disorders
13.4.3. Oncology
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Retinoic Acid Receptor Beta Market Size and Volume Forecast by Type
13.7.1. Alitretinoin
13.7.2. SBD-073
13.7.3. Tamibarotene
13.7.4. Tazarotene
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Retinoic Acid Receptor Beta Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Retinoic Acid Receptor Beta Market: Market Share Analysis
14.2. Retinoic Acid Receptor Beta Distributors and Customers
14.3. Retinoic Acid Receptor Beta Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. 3SBio Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Lee's Pharmaceutical Holdings Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Phosphagenics Ltd
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Promius Pharma LLC
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sol-Gel Technologies Ltd
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Valeant Pharmaceuticals International Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
